Table 1. Baseline characteristics of study population.
| KRAS WT (N = 55) | KRAS MT (N = 38) | p-value | |
|---|---|---|---|
| Age, mean (SD) | 58.0 (±11.6) | 62.8 (±11.8) | P = 0.06 |
|
Sex, n(%) Male Female |
31 (56) 24 (43) |
15 (39) 23 (61) |
p = 0.11 |
|
Race, n(%) White African-American Asian |
45 (82) 8 (15) 2 (4) |
34 (89) 4 (11) 0 (0) |
p = 0.60 |
|
Smoking status, n(%) Never Former Current |
16 (29) 27 (49) 12 (22) |
3 (8) 23 (60) 12 (32) |
p = 0.04 |
| Pack-years, mean (SD) | 37.0 (23.5) | 34.0 (26.9) | p = 0.62 |
|
ECOG performance status, n(%) 0 1 2 |
18 (32) 30 (55) 7 (13) |
15 (39) 15 (39) 8 (21) |
p = 0.34 |
|
Platinum chemotherapy, n(%) Carboplatin Cisplatin |
53 (96) 2 (4) |
36 (95) 5 (5) |
|
| Pemetrexed, n(%) | 42 (76) | 31 (82) | p = 0.55 |
| Bevacizumab, n(%) | 26 (47) | 16 (42) | p = 0.62 |